Home / Countries / Poland

WHO European Region · country profile

HIV, PrEP and sexual health access in Poland

Poland: 86% of verified HIV medicine records are reimbursed; PrEP is available but not reimbursed; sexuality education is classified as restricted. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 14/09/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

Read more: HIV medicines in PolandPrEP in PolandDoxyPEP in PolandSexuality education in PolandAbortion and contraception rules in PolandHealthcare for migrants in Poland

HIV medicines86% reimbursed30 of 35 verified recordsPrEPAvailable, not reimbursed3,000 PrEP recipients (2022; UNAIDS GAM)DoxyPEPNot available / no guidelinesNational access and guidanceSexuality educationRestrictedPolicy frameworkFamily planning & abortionHighly restrictedAbortion law and contraceptionMigrant healthcare accessWarningEntitlement and practice

7 HIV medicine records for Poland are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Poland?

Of 35 verified HIV medicine records for Poland, 30 are available and reimbursed (86%), 3 are available but not reimbursed and 2 are not available. 7 further records are still under review.

Reimbursed 30

Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Emtriva, Epivir, Eviplera, Genvoya, Intelence, Isentress, Juluca, Kaletra and 16 more

Available, not reimbursed 3

Generic TDF/FTC (Emtricitabine/Tenofovir DF), Rukobia, Sunlenca

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in Poland?

PrEP is available in Poland, but SHAPE's review did not find it reimbursed.

PrEP recipients: 3,000 PrEP recipients (2022; UNAIDS GAM)

UNAIDS GAM 2025 reports 3,000 people receiving PrEP in 2022. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Poland?

SHAPE's review found no national DoxyPEP programme or guideline in Poland.

No country-specific national DoxyPEP programme was confirmed in this review. WHO's 14 July 2026 guideline conditionally recommends that DoxyPEP may be offered to men who have sex with men and transgender women as part of a comprehensive sexual health package. It prioritizes people with recent or recurrent bacterial STIs and calls for antimicrobial-resistance monitoring; the guideline does not itself establish country-level availability or reimbursement. [Source: https://www.who.int/publications/i/item/9789240124110]

What is the policy on sexuality education in Poland?

SHAPE classifies the sexuality education framework in Poland as restricted. This describes the national policy framework, not how every school delivers it.

  • National framework: Family Life Education is optional and subject to parental opt-out; the curriculum is not equivalent to comprehensive rights-based sexuality education and emphasizes traditional family norms.
  • Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Poland?

SHAPE classifies family planning and abortion rights in Poland as highly restricted, combining abortion law and contraception policy.

  • Abortion: Abortion is lawful only when pregnancy threatens life or health or results from a criminal act; the fetal-impairment ground was removed in 2021 and practical access remains highly restricted.
  • Pending change (not in force): On 20 October 2026 the Sejm passed two bills, one restoring abortion for severe foetal abnormality (233 to 203) and one decriminalising assistance in obtaining an abortion (217 to 213). Both still need the Senate and the President's signature, and a veto is considered likely, so the current law and status are unchanged.
  • Contraception: EPF's 2026 contraception-policy score is 38.9%; the atlas records limited national coverage.
  • Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/country/poland/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf ; https://notesfrompoland.com/2026/10/21/parliament-approves-liberalisation-of-polands-abortion-laws/]

Can migrants access healthcare in Poland?

SHAPE's editorial comparison places migrant healthcare access in Poland in the middle category (Warning). Entitlement: Insurance- and protection-status based; emergency/necessary care floor.

Provider type: National Health Fund / reception services / NGO · International migrants (2024): 1,739,901

  • Access rule: Insured or otherwise eligible residents and temporary-protection beneficiaries use public coverage; asylum applicants receive care through reception arrangements.
  • Main barriers: Undocumented adults have restricted routine access and may face payment, documentation, language and referral barriers.
  • Migration measure: UN DESA estimates 1,739,901 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
  • Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
  • Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
  • Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Ukraine (63.4%), United Kingdom (10.6%), Germany (5%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 30.7%

How Poland compares

Poland ranks #12 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (86%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

All HIV medicines in Poland

MedicineActive ingredientClassStatusEvidence and sourceChecked
Biktarvy
Gilead Sciences
Bictegravir / Emtricitabine / TAFINSTI + NRTI/NtRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Celsentri
ViiV Healthcare
MaravirocEntry InhibitorReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Delstrigo
Merck
Doravirine / Lamivudine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Descovy
Gilead Sciences
Emtricitabine / TAFNRTIReimbursedTreatment: reimbursed through the National ARV Programme. PrEP: full out-of-pocket. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Dovato
ViiV Healthcare
Dolutegravir / LamivudineINSTI + NRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Edurant
Janssen
RilpivirineNNRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Emtriva
Gilead Sciences
EmtricitabineNRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Epivir
ViiV Healthcare
LamivudineNRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Eviplera
Gilead Sciences
Rilpivirine / Emtricitabine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Genvoya
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / TAFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Intelence
Janssen
EtravirineNNRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Isentress
Merck
RaltegravirINSTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Juluca
ViiV Healthcare
Dolutegravir / RilpivirineINSTI + NNRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Kaletra
AbbVie
Lopinavir / RitonavirPIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Kivexa
ViiV Healthcare
Abacavir / LamivudineNRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Norvir
AbbVie
RitonavirPI + pharmacokinetic enhancerReimbursedProcured centrally by MoH through the National ARV Programme. EU regulatory update (as of 5 Oct 2026): on 18 September 2025 the CHMP adopted a positive opinion recommending changes to the existing indication and contraindications of Norvir, including guidance that when ritonavir is used as a pharmacokinetic enhancer the SmPC of the co-administered protease inhibitor should be consulted for contraindications. European Commission decision not confirmed during this review. [Sources: Local Ministry of Health / ECDC reports; https://www.ema.europa.eu/en/medicines/human/variation/norvir]14/09/2026
Odefsey
Gilead Sciences
Rilpivirine / Emtricitabine / TAFNNRTI + NRTI/NtRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Pifeltro
Merck
DoravirineNNRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Prezista
Janssen
DarunavirPIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Rekambys
Janssen
RilpivirineLong-Acting NNRTIReimbursedProvided through the National ARV Programme for treatment, co-administered with Vocabria. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Retrovir
ViiV Healthcare
ZidovudineNRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Rezolsta
Janssen
Darunavir / CobicistatPI + pharmacokinetic enhancerReimbursedProcured centrally by the Ministry of Health through the National ARV Programme. EMA's CHMP adopted a positive opinion on 25 June 2026 for a new dispersible formulation and a paediatric indication from age 3 years and body weight 15 kg; Polish reimbursement of the new formulation has not been confirmed. [Sources: Polish National ARV Programme; https://www.ema.europa.eu/en/medicines/human/variation/rezolsta]14/09/2026
Stribild
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Symtuza
Janssen
Darunavir / Cobicistat / Emtricitabine / TAFPI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.ema.europa.eu/en/medicines/human/variation/symtuza]14/09/2026
Tivicay
ViiV Healthcare
DolutegravirINSTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Triumeq
ViiV Healthcare
Dolutegravir / Abacavir / LamivudineINSTI + NRTIReimbursedProvided free of charge to all patients through the centralized National HIV/AIDS Program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Truvada
Gilead Sciences
Emtricitabine / Tenofovir DFNRTIReimbursedTreatment: reimbursed through the National ARV Programme. PrEP: full out-of-pocket. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Viread
Gilead Sciences
Tenofovir DFNtRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Vocabria
ViiV Healthcare
CabotegravirINSTIReimbursedProvided through the National ARV Programme for treatment, always co-administered with Rekambys. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Ziagen
ViiV Healthcare
AbacavirNRTIReimbursedProcured centrally by MoH through the National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF)
Multiple (Generics)
Emtricitabine / Tenofovir DFNRTIAvailable, not reimbursedGenerics are on the market but only full out-of-pocket retail; not used in the Programme (originals only) and PrEP isn't reimbursed at all. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Rukobia
ViiV Healthcare
FostemsavirAttachment InhibitorAvailable, not reimbursedRegistered but not yet included in the centralized public procurement list of the national HIV program. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Sunlenca
Gilead Sciences
LenacapavirCapsid InhibitorAvailable, not reimbursedConfirmed registered in PL, but NOT in the current 2022–2026 National ARV Programme. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir)
Multiple (Generics)
Tenofovir DF / Lamivudine / DolutegravirINSTI + NRTI/NtRTINot availableNational programs generally prioritize original branded regimens over generic combinations. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz)
Multiple (Generics)
Tenofovir DF / Lamivudine / EfavirenzNNRTI + NRTI/NtRTINot availableNational programs generally prioritize original branded regimens over generic combinations. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Apretude
ViiV Healthcare
Cabotegravir (PrEP)INSTI (Long-Acting PrEP)Under reviewLong-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis in adults and adolescents from 12 years weighing at least 35 kg. EMA confirms an EU/EEA-wide marketing authorisation granted by the European Commission on 19 September 2023. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude]14/09/2026
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris
Viatris Limited
Emtricitabine / Rilpivirine / Tenofovir alafenamideNNRTI + NRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris]14/09/2026
Emtricitabine / Tenofovir alafenamide Viatris
Viatris Limited
Emtricitabine / Tenofovir alafenamideNRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris]14/09/2026
Evotaz
Bristol Myers Squibb
Atazanavir / CobicistatPI + pharmacokinetic enhancerUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 13 July 2015. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz]14/09/2026
Reyataz
Bristol Myers Squibb
AtazanavirPIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 2 March 2004. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz]14/09/2026
Vocabria / Rekambys
ViiV Healthcare / Janssen
Cabotegravir / RilpivirineLong-Acting ARTUnder reviewCountry-level marketing, supply and reimbursement have not yet been verified. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Source: https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Yeytuo
Gilead Sciences
Lenacapavir (PrEP)Capsid Inhibitor (Long-Acting PrEP)Under reviewTwice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

  • aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
  • who.int https://www.who.int/publications/i/item/9789240124110
  • unesco.org https://www.unesco.org/gem-report/en/peer
  • who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
  • bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
  • abortion-policies.srhr.org https://abortion-policies.srhr.org/country/poland/
  • epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
  • notesfrompoland.com https://notesfrompoland.com/2026/10/21/parliament-approves-liberalis…
  • who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
  • ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
  • home-affairs.ec.europa.eu https://home-affairs.ec.europa.eu/policies/migration-and-asylum/asyl…
  • health.ec.europa.eu https://health.ec.europa.eu/social-determinants/migrants-health_en
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilp…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-teno…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/norvir
  • pharmiweb.com https://www.pharmiweb.com/press-release/2025-01-31/european-commissi…
  • i-base.info https://i-base.info/htb/50121
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/rezolsta
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/symtuza
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo

Explore more

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.